Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates.

Publication ,  Journal Article
Reiss, EIMM; van Haaren, MM; van Schooten, J; Claireaux, MAF; Maisonnasse, P; Antanasijevic, A; Allen, JD; Bontjer, I; Torres, JL; Lee, W-H ...
Published in: NPJ Vaccines
November 25, 2022

The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutralizing antibodies (NAbs) against HIV-1. The clinical candidate immunogen ConM SOSIP.v7 is a stabilized native-like HIV-1 Env trimer based on an artificial consensus sequence of all HIV-1 isolates in group M. In preclinical studies ConM SOSIP.v7 trimers induced strong autologous NAb responses in non-human primates (NHPs). To fine-map these responses, we isolated monoclonal antibodies (mAbs) from six cynomolgus macaques that were immunized three times with ConM SOSIP.v7 protein and boosted twice with the closely related ConSOSL.UFO.664 immunogen. A total of 40 ConM and/or ConS-specific mAbs were isolated, of which 18 were retrieved after the three ConM SOSIP.v7 immunizations and 22 after the two immunizations with ConSOSL.UFO.664. 22 mAbs (55%) neutralized the ConM and/or ConS virus. Cross-neutralization of ConS virus by approximately one-third of the mAbs was seen prior to ConSOSL.UFO.664 immunization, albeit with modest potency. Neutralizing antibodies predominantly targeted the V1 and V2 regions of the immunogens, with an apparent extension towards the V3 region. Thus, the V1V2V3 region is immunodominant in the potent NAb response elicited by two consensus sequence native-like HIV-1 Env immunogens. Immunization with these soluble consensus Env proteins also elicited non-neutralizing mAbs targeting the trimer base. These results inform the use and improvement of consensus-based trimer immunogens in combinatorial vaccine strategies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

NPJ Vaccines

DOI

EISSN

2059-0105

Publication Date

November 25, 2022

Volume

7

Issue

1

Start / End Page

152

Location

England

Related Subject Headings

  • 3207 Medical microbiology
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reiss, E. I. M. M., van Haaren, M. M., van Schooten, J., Claireaux, M. A. F., Maisonnasse, P., Antanasijevic, A., … van Gils, M. J. (2022). Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates. NPJ Vaccines, 7(1), 152. https://doi.org/10.1038/s41541-022-00576-9
Reiss, E. I. M. M., M. M. van Haaren, J. van Schooten, M. A. F. Claireaux, P. Maisonnasse, A. Antanasijevic, J. D. Allen, et al. “Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates.NPJ Vaccines 7, no. 1 (November 25, 2022): 152. https://doi.org/10.1038/s41541-022-00576-9.
Reiss EIMM, van Haaren MM, van Schooten J, Claireaux MAF, Maisonnasse P, Antanasijevic A, et al. Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates. NPJ Vaccines. 2022 Nov 25;7(1):152.
Reiss, E. I. M. M., et al. “Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates.NPJ Vaccines, vol. 7, no. 1, Nov. 2022, p. 152. Pubmed, doi:10.1038/s41541-022-00576-9.
Reiss EIMM, van Haaren MM, van Schooten J, Claireaux MAF, Maisonnasse P, Antanasijevic A, Allen JD, Bontjer I, Torres JL, Lee W-H, Ozorowski G, Vázquez Bernat N, Kaduk M, Aldon Y, Burger JA, Chawla H, Aartse A, Tolazzi M, Gao H, Mundsperger P, Crispin M, Montefiori DC, Karlsson Hedestam GB, Scarlatti G, Ward AB, Le Grand R, Shattock R, Dereuddre-Bosquet N, Sanders RW, van Gils MJ. Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates. NPJ Vaccines. 2022 Nov 25;7(1):152.

Published In

NPJ Vaccines

DOI

EISSN

2059-0105

Publication Date

November 25, 2022

Volume

7

Issue

1

Start / End Page

152

Location

England

Related Subject Headings

  • 3207 Medical microbiology
  • 3204 Immunology